Where Will the Next Generation of Stroke Treatments Come From?

1. LearyMC

SaverJL

2003 Annual incidence of first silent stroke in the United States: a preliminary estimate. Cerebrovasc Dis 16 280 285

2. DonnanGA

FisherM

MacleodM

DavisSM

2008 Stroke. Lancet 371 1612 1623

3. MergenthalerP

DirnaglU

MeiselA

2004 Pathophysiology of stroke: lessons from animal models. Metab Brain Dis 19 151 167

4. DonnanG

BaronJ

DavisS

SharpF

2006 The Ischaemic Penumbra: history, current status and implications for therapy. New York Informa Health Care Inc

5. PROGRESS Collaborative Group 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 1033 1041

6. KizerJR

DahlofB

KjeldsenSE

JuliusS

BeeversG

2005 Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension 45 46 52

7. AmarencoP

BogousslavskyJ

CallahanA3rd

GoldsteinLB

HennericiM

2006 High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 355 549 559

8. GrangerCB

WhiteHD

BatesER

OhmanEM

CaliffRM

1994 A pooled analysis of coronary arterial patency and left ventricular function after intravenous thrombolysis for acute myocardial infarction. Am J Cardiol 74 1220 1228

9. VahediK

HofmeijerJ

JuettlerE

VicautE

GeorgeB

2007 Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol 6 215 222

10. LanghorneP

WilliamsBO

GilchristW

HowieK

1993 Do stroke units save lives? Lancet 342 395 398

11. FeiginVL

LawesCM

BennettDA

AndersonCS

2003 Stroke epidemiology: a review of population-based studies of incidence, prevalence, and case-fatality in the late 20th century. Lancet Neurol 2 43 53

12. BonitaR

BeagleholeR

1989 Increased treatment of hypertension does not explain the decline in stroke mortality in the United States, 1970–1980. Hypertension 13 I69 73

13. BejotY

Ben SalemD

OssebyGV

CouvreurG

DurierJ

2009 Epidemiology of ischemic stroke from atrial fibrillation in Dijon, France, from 1985 to 2006. Neurology 72 346 353

14. ConnollySJ

EzekowitzMD

YusufS

EikelboomJ

OldgrenJ

2009 Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 1139 1151

15. KwonHM

KimBJ

ParkJH

RyuWS

KimCK

2009 Significant association of metabolic syndrome with silent brain infarction in elderly people. J Neurol

16. LovshinJA

DruckerDJ

2009 Incretin-based therapies for type 2 diabetes mellitus. Nat Rev Endocrinol 5 262 269

17. DienerHC

2006 Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? Int J Stroke 1 4 8

18. HoksbergenAW

MajoieCB

HulsmansFJ

LegemateDA

2003 Assessment of the collateral function of the circle of Willis: three-dimensional time-of-flight MR angiography compared with transcranial color-coded duplex sonography. AJNR Am J Neuroradiol 24 456 462

19. MiteffF

LeviCR

BatemanGA

SprattN

McElduffP

2009 The independent predictive utility of computed tomography angiographic collateral status in acute ischaemic stroke. Brain 132 2231 2238

20. BiswasA

TiwariAK

RanjanR

MeenaA

AkhterMS

2009 Prothrombotic polymorphisms, mutations, and their association with pediatric non-cardioembolic stroke in Asian-Indian patients. Ann Hematol 88 473 478

21. AdamskiMG

TurajW

SlowikA

Wloch-KopecD

WolkowP

2009 A-G-4G haplotype of PAI-1 gene polymorphisms −844 G/A, HindIII G/C, and −675 4G/5G is associated with increased risk of ischemic stroke caused by small vessel disease. Acta Neurol Scand 120 94 100

22. GilliganAK

ThriftAG

SturmJW

DeweyHM

MacdonellRA

2005 Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit? Cerebrovasc Dis 20 239 244

23. DawsonTM

DawsonVL

2006 Taming the clot-buster tPA. Nat Med 12 993 994

24. BluhmkiE

ChamorroA

DavalosA

MachnigT

SauceC

2009 Stroke treatment with alteplase given 3.0–4.5 h after onset of acute ischaemic stroke (ECASS III): additional outcomes and subgroup analysis of a randomised controlled trial. Lancet Neurol 8 1095 1102

25. HackeW

KasteM

BluhmkiE

BrozmanM

DavalosA

2008 Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 359 1317 1329

26. SuEJ

FredrikssonL

GeyerM

FolestadE

CaleJ

2008 Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke. Nat Med 14 731 737

27. LadenvallC

GilsA

JoodK

BlomstrandC

DeclerckPJ

2007 Thrombin activatable fibrinolysis inhibitor activation peptide shows association with all major subtypes of ischemic stroke and with TAFI gene variation. Arterioscler Thromb Vasc Biol 27 955 962

28. BrounsR

HeylenE

SheorajpandayR

WillemseJL

KunnenJ

2009 Carboxypeptidase U (TAFIa) decreases the efficacy of thrombolytic therapy in ischemic stroke patients. Clin Neurol Neurosurg 111 165 170

29. SemeraroF

AmmolloCT

SemeraroN

ColucciM

2009 Tissue factor-expressing monocytes inhibit fibrinolysis through a TAFI-mediated mechanism, and make clots resistant to heparins. Haematologica 94 819 826

30. BajzarL

NesheimME

TracyPB

1996 The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 88 2093 2100

31. BirdE

TamuraJ

BostwickJS

SteinbacherTE

StewartA

2007 Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats? Thromb Res 120 549 558

32. SmithWS

SungG

StarkmanS

SaverJL

KidwellCS

2005 Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke 36 1432 1438

33. BoseA

HenkesH

AlfkeK

ReithW

MayerTE

2008 The Penumbra System: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol 29 1409 1413

34. MacleodMR

FisherM

O'CollinsV

SenaES

DirnaglU

2009 Good laboratory practice: preventing introduction of bias at the bench. Stroke 40 e50 52

35. SenaE

van der WorpHB

HowellsD

MacleodM

2007 How can we improve the pre-clinical development of drugs for stroke? Trends Neurosci 30 433 439

36. STAIR 1999 Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 30 2752 2758

37. van der WorpHB

SenaES

DonnanGA

HowellsDW

MacleodMR

2007 Hypothermia in animal models of acute ischaemic stroke: a systematic review and meta-analysis. Brain 130 3063 3074

38. BernardS

2006 Therapeutic hypothermia after cardiac arrest: now a standard of care. Crit Care Med 34 923 924

39. SalussoliaCL

NalwalkJW

HoughLB

2007 Improgan-induced hypothermia: a role for cannabinoid receptors in improgan-induced changes in nociceptive threshold and body temperature. Brain Res 1152 42 48

40. AslamiH

SchultzMJ

JuffermansNP

2009 Potential applications of hydrogen sulfide-induced suspended animation. Curr Med Chem 16 1295 1303

41. SesslerDI

2009 Defeating normal thermoregulatory defenses: induction of therapeutic hypothermia. Stroke 40 e614 621

42. HenningerN

BouleyJ

NelliganJM

SicardKM

FisherM

2007 Normobaric hyperoxia delays perfusion/diffusion mismatch evolution, reduces infarct volume, and differentially affects neuronal cell death pathways after suture middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 27 1632 1642

43. SinghalAB

BennerT

RoccatagliataL

KoroshetzWJ

SchaeferPW

2005 A pilot study of normobaric oxygen therapy in acute ischemic stroke. Stroke 36 797 802

44. HoltmaatA

SvobodaK

2009 Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci 10 647 658

45. CurtisMA

ErikssonPS

FaullRL

2007 Progenitor cells and adult neurogenesis in neurodegenerative diseases and injuries of the basal ganglia. Clin Exp Pharmacol Physiol 34 528 532

46. KuhlmannT

MironV

CuoQ

WegnerC

AntelJ

2008 Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain 131 1749 1758

47. JohanssonBB

2000 Brain plasticity and stroke rehabilitation. The Willis lecture. Stroke 31 223 230

48. MinnerupJ

HeidrichJ

WellmannJ

RogalewskiA

SchneiderA

2008 Meta-analysis of the efficacy of granulocyte-colony stimulating factor in animal models of focal cerebral ischemia. Stroke 39 1855 1861

49. DaadiMM

MaagAL

SteinbergGK

2008 Adherent self-renewable human embryonic stem cell-derived neural stem cell line: functional engraftment in experimental stroke model. PLoS One 3 e1644

50. OttHC

MatthiesenTS

GohSK

BlackLD

KrenSM

2008 Perfusion-decellularized matrix: using nature's platform to engineer a bioartificial heart. Nat Med 14 213 221

51. DirnaglU

SchwabJM

2009 Brain-immune interactions in acute and chronic brain disorders. Neuroscience 158 969 971

52. BatchelorPE

LiberatoreGT

WongJY

PorrittMJ

FrerichsF

1999 Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor. J Neurosci 19 1708 1716

53. LoEH

2008 A new penumbra: transitioning from injury into repair after stroke. Nat Med 14 497 500

54. WhisnantJ

1997 Modeling of risk factors for ischemic stroke. The Willis Lecture. Stroke 28 1840 1844

55. LouviA

Arboleda-VelasquezJF

Artavanis-TsakonasS

2006 CADASIL: a critical look at a Notch disease. Dev Neurosci 28 5 12

56. BilguvarK

YasunoK

NiemelaM

RuigrokYM

von Und Zu FraunbergM

2008 Susceptibility loci for intracranial aneurysm in European and Japanese populations. Nat Genet 40 1472 1477

57. GschwendtnerA

BevanS

ColeJW

PlourdeA

MatarinM

2009 Sequence variants on chromosome 9p21.3 confer risk for atherosclerotic stroke. Ann Neurol 65 531 539

58. 1995 Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med 333 1581 1587

59. 1997 The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. International Stroke Trial Collaborative Group. Lancet 349 1569 1581

60. MayerSA

BrunNC

BegtrupK

BroderickJ

DavisS

2005 Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 777 785

61. MendelowAD

GregsonBA

FernandesHM

MurrayGD

TeasdaleGM

2005 Early surgery versus initial conservative treatment in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet 365 387 397

62. HackeW

AlbersG

Al-RawiY

BogousslavskyJ

DavalosA

2005 The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke 36 66 73

63. AlexandrovAV

MolinaCA

GrottaJC

GaramiZ

FordSR

2004 Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med 351 2170 2178

64. 2006 Glyceryl trinitrate vs. control, and continuing vs. stopping temporarily prior antihypertensive therapy, in acute stroke: rationale and design of the Efficacy of Nitric Oxide in Stroke (ENOS) trial (ISRCTN99414122). Int J Stroke 1 245 249

65. LeesKR

ZivinJA

AshwoodT

DavalosA

DavisSM

2006 NXY-059 for acute ischemic stroke. N Engl J Med 354 588 600

66. 1978 A randomized trial of aspirin and sulfinpyrazone in threatened stroke. The Canadian Cooperative Study Group. N Engl J Med 299 53 59

67. DienerHC

CunhaL

ForbesC

SiveniusJ

SmetsP

1996 European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143 1 13

68. CAPRIE Steering Committee 1996 A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 348 1329 1339

69. 1993 Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet 342 1255 1262

70. 1991 Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 325 445 453

71. 1991 MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 337 1235 1243

72. 2001 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 358 1033 1041

73. AmarencoP

BogousslavskyJ

CallahanA

GoldsteinLB

HennericiM

2006 High-dose atorvastatin after stroke or transient ischemic attack. New England Journal of Medicine 355 549 559

74. YadavJS

WholeyMH

KuntzRE

FayadP

KatzenBT

2004 Protected carotid-artery stenting versus endarterectomy in high-risk patients. N Engl J Med 351 1493 1501